|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.10 / 0.19|
The trading panel says tech is still good, but don't forget to take profits.
Here are some of the stocks the 'Fast Money' crew has been talking about lately.
A European advisory committee recommends the drug be approved for use as a first-line treatment for colorectal cancer.
The drugmaker will pay $5.50 a share for the biotech company, a $190 million deal that will enhance its cancer drug portfolio.
The much-anticipated overall survival data for lung cancer Erbitux will be released June 1.
The company shared the news late Thursday and said data will now be available a year earlier than expected.
Abbott Labs climbs on new data from its Spirit III trial for its Xience V stent.
The biotech stock has fallen ahead of ASCO on doubts about the FLEX study, but management remains bullish.
The American Society of Clinical Oncology, for the first time, is making research abstracts freely available to everyone ahead of the cancer drug confab. Here's a cheat sheet.
Outlooks for SuperGen's Dacogen and Myriad Genetics' Flurizan; more Q&A on ImClone's Erbitux, and more.
What to expect when ImClone presents the latest Erbitux data at ASCO in June.
But factoring out acquisition costs, the drugmaker beats Wall Street's first-quarter estimates.
The biotech company posts first-quarter profit and revenue that just exceed expectations.
U.S. regulators say Myozyme produced at the 160-liter bioreactor scale and the same drug made at the 2,000-liter scale should be classified as two different products.
The failure shouldn't immediately threaten revenue, but could make doctors re-evaluate use.
If you can spot red flags in data presentations, you can avoid getting suckered into biotech money traps.
The Big Pharma will assume all development costs for CDX-110 and pay royalties to the biotech on the sales if the drug's approved.
The panel says the pharma company was right to stand up for its anemia patent.
Is the lower paid clicks issue a problem for Google, and the first bathroom in America.
Is there a plunge protection team boosting the markets, and what happens after large Dow moves?
How are healthcare, pharmaceutical and biotech ETFs holding up in the market turmoil?
Avastin's approval could spark Genentech to boost earnings guidance.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.